Want to see SE:CANTA full AI Analyst Report?
Top Page
Cantargia AB
(CANTA)
Select Model
Select Model
Rating:74Outperform
Price Target:
kr2.00
▼(-50.86% Downside)
Action:Reiterated
Date:08/25/26
The score is driven primarily by strong current financial performance—exceptional margins, strong free cash flow that closely matches earnings, and a debt-free balance sheet. Valuation also supports the rating due to a very low P/E. Offsetting these positives, technicals point to a weaker longer-term price trend (below the 50/100/200-day averages), and the historical pattern of zero-revenue/loss years makes the sustainability of the recent profit base a key risk.
Positive Factors
Strong profitability
The sharp move to high operating and net margins improves internal funding capacity and demonstrates strong economics in the latest period. If maintained, profitability could reduce reliance on external capital while supporting continued development.
Negative Factors
Highly volatile earnings base
The contrast between recent profits and several years of losses indicates that earnings may be lumpy and dependent on milestone or one-time items. This weakens confidence that current margins and cash generation represent a stable recurring business base.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong profitability
The sharp move to high operating and net margins improves internal funding capacity and demonstrates strong economics in the latest period. If maintained, profitability could reduce reliance on external capital while supporting continued development.
Read all positive factors
Cantargia AB (CANTA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr552.61M
Dividend YieldN/A
Average Volume (3M)1.42M
Price to Earnings (P/E)2.9
Beta (1Y)0.82
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.68
Shares Outstanding281,944,980
10 Day Avg. Volume1,074,033
30 Day Avg. Volume1,417,172
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.91
Price to Sales (P/S)3.28
P/FCF Ratio6.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr12.00Price Target Upside194.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.77
Revenue Forecast (FY)kr1.05M
Cantargia AB Business Overview & Revenue Model
Company Description
Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to t...
How the Company Makes Money
Cantargia primarily makes money through external financing and partnering rather than commercial product sales, as its key assets are (or have been) in clinical development. The main expected/actual revenue sources are: (1) Collaboration and licen...
Cantargia AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
72
Positive
Cash Flow
85
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 317.31M | 316.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 316.06M | 313.43M | -3.44M | -3.45M | -3.69M | -3.45M |
| EBITDA | 166.85M | 154.37M | -165.05M | -284.31M | -368.12M | -363.06M |
| Net Income | 167.38M | 146.97M | -161.65M | -280.03M | -371.81M | -366.50M |
Balance Sheet | ||||||
| Total Assets | 307.69M | 296.66M | 170.43M | 223.71M | 474.80M | 600.24M |
| Cash, Cash Equivalents and Short-Term Investments | 221.96M | 281.82M | 33.04M | 194.75M | 426.67M | 559.39M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 43.89M | 30.78M | 54.12M | 54.97M | 85.11M | 67.50M |
| Stockholders Equity | 263.80M | 265.88M | 116.30M | 168.74M | 389.68M | 532.75M |
Cash Flow | ||||||
| Free Cash Flow | 164.72M | 149.66M | -162.75M | -286.66M | -366.00M | -346.83M |
| Operating Cash Flow | 164.78M | 150.13M | -162.75M | -286.66M | -358.92M | -346.44M |
| Investing Cash Flow | -12.06M | -472.00K | 55.00M | 182.09M | 67.88M | -102.43M |
| Financing Cash Flow | -25.46M | 103.86M | -1.07M | 54.68M | 223.93M | 3.00K |
Cantargia AB Technical Analysis
Neutral
4.07
Price Trends
1.94
Positive
2.57
Negative
3.50
Negative
Market Momentum
>-0.01
Negative
53.43
Neutral
61.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CANTA, the sentiment is Neutral. The current price of 4.07 is above the 20-day moving average (MA) of 1.84, above the 50-day MA of 1.94, and above the 200-day MA of 3.50, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.43 is Neutral, neither overbought nor oversold. The STOCH value of 61.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CANTA.
Cantargia AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr552.61M | 2.86 | 77.69% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr256.39M | -3.94 | -59.93% | ― | ― | 32.66% | |
48 Neutral | kr648.71M | -2.18 | ― | ― | 87.23% | 35.27% | |
48 Neutral | kr439.60M | -3.97 | -17.87% | ― | ― | 15.97% | |
43 Neutral | kr1.55B | -4.44 | -53.88% | ― | -87.22% | -70.29% | |
42 Neutral | kr176.52M | -8.88 | -56.67% | ― | ― | 43.32% |
* Healthcare Sector Average
SE:CANTA
Cantargia AB
1.94
-0.80
-29.18%
SE:BINV
BioInvent International AB
22.60
-8.45
-27.21%
SE:ONCO
Oncopeptides AB
2.05
-2.67
-56.54%
SE:ISOFOL
Isofol Medical AB
0.80
-0.04
-4.86%
SE:ELIC
Elicera Therapeutics AB
2.58
-4.31
-62.62%
SE:IMMU
Immunicum AB
7.11
-0.12
-1.66%
Cantargia AB Corporate Events
Cantargia details pipeline and financials in H1 2026 interim report
Aug 19, 2026
Cantargia AB has released its interim report for January to June 2026, offering a translated version for non‑Swedish investors while maintaining the Swedish original as the prevailing document. The report outlines the company’s pipelin...
Cantargia schedules Q2 2026 results release and investor conference call
Aug 4, 2026
Cantargia will publish its interim report for January to June 2026 on August 19 and host a quarterly conference call that afternoon for investors, analysts and media, led by CEO Hilde Steineger and CFO Patrik Renblad. Management plans to review th...
Cantargia Expands Share Capital After Rights Issue Completion
Jul 31, 2026
Cantargia AB has expanded its share capital following the completion of a recent rights issue, increasing the number of shares and voting rights by 33,333,333. As of the last trading day of July, the company now has a total of 281,944,988 shares a...
Cantargia Data Strengthen IL1RAP and Nadunolimab Case in Pancreatic Cancer
Jun 26, 2026
Cantargia has reported new preclinical and clinical data in JCI Insight supporting IL1RAP as a key therapeutic target and predictive biomarker in pancreatic ductal adenocarcinoma, reinforcing the rationale for its lead antibody nadunolimab. The fi...
Cantargia Raises SEK 75 Million in Undersubscribed Rights Issue and Grants Warrants to Fenja Capital
Jun 23, 2026
Cantargia has completed a rights issue that was subscribed to approximately 21 percent, including both subscriptions with and without preferential rights, resulting in gross proceeds of about SEK 75 million to support its development plan and stra...
Cantargia Highlights Nadunolimab’s Pancreatic Cancer Potential in Upcoming KOL Call
Jun 11, 2026
Cantargia is organizing a key opinion leader call with H.C. Wainwright on June 22 to highlight IL1RAP as a therapeutic target in pancreatic ductal adenocarcinoma and to discuss the clinical potential of its anti-IL1RAP antibody nadunolimab. The ev...
Cantargia Launches Phase 2 Prevention Trial of Nadunolimab in High‑Risk Lung Cancer Patients
Jun 10, 2026
Cantargia has begun a Phase 2, investigator‑initiated trial of its IL1RAP‑targeting antibody nadunolimab as a preventive therapy in up to 59 current or former smokers with multifocal high‑risk lung nodules at Mount Sinai’s ...
Cantargia launches SEK 124m rights issue to fund antibody pipeline
Jun 5, 2026
Cantargia AB has published an information document for a previously announced rights issue of approximately SEK 124 million, prepared under the EU Prospectus Regulation framework and now registered with the Swedish Financial Supervisory Authority....
Cantargia Raises Up to SEK 199 Million to Advance Nadunolimab Oncology Pipeline
May 28, 2026
Cantargia AB has launched a SEK 124 million rights issue and secured a loan agreement of up to SEK 75 million from Fenja Capital to strengthen its balance sheet and fund key clinical initiatives. Existing shareholders receive preferential rights t...
Cantargia Raises Funds to Expand Nadunolimab Strategy in Cancer and Blood Disorders
May 28, 2026
Cantargia AB plans to host a webcast on June 1 to outline a rights issue and loan agreement designed to bolster its finances and support an expanded clinical development strategy. The capital injection aims to fund additional work on nadunolimab, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.